Skip to main content

Full Schedule

Full Schedule

  • Thursday, September 28, 2023
  • 8:00 AM – 8:15 AM ET
    Welcome
  • 8:15 AM – 8:30 AM ET
    1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant Immunotherapy
  • 8:30 AM – 8:45 AM ET
    1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant Immunotherapy
  • 8:45 AM – 9:00 AM ET
    1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers
  • 9:00 AM – 9:15 AM ET
    Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined Immunotherapy
  • 9:15 AM – 9:30 AM ET
    Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Chemotherapy
  • 9:30 AM – 9:45 AM ET
    Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC)
  • 9:45 AM – 9:50 AM ET
    Break
  • 9:50 AM – 10:50 AM ET
    Non-CME Innovation Theater (Sponsored By Merck)
  • 10:50 AM – 11:00 AM ET
    Exhibit Hall
  • 11:00 AM – 11:35 AM ET
    3 - Session 3: Perspectives on Clinical Trial Development in Anal Cancer

    Invited Speaker: Aaron J. Scott, MD – University of Arizona Cancer Center

  • 11:35 AM – 11:45 AM ET
    3 - Session 3: Therapeutic Sequencing in Advanced Colorectal Cancer: New Strategies from Clinical Trial Data

    Moderator: Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center

    Moderator: David H. Ilson, MD, PhD – Weill Cornell Medical College, Memorial Hospital, Memorial Sloan Kettering Cancer Center

    Invited Speaker: Aaron J. Scott, MD – University of Arizona Cancer Center

  • 11:45 AM – 12:20 PM ET
    Session 4: Circulating Tumor DNA (ctDNA) in Gastrointestinal Malignancies
  • 12:20 PM – 12:30 PM ET
    Live Q&A
  • 12:30 PM – 12:35 PM ET
    Break
  • 12:35 PM – 1:35 PM ET
    Non-CME Innvoation Theater (Sponsored By Astellas)
  • 1:35 PM – 2:10 PM ET
    Session 5: Advances in Neuroendocrine Tumors (NETs)
  • 2:10 PM – 2:20 PM ET
    Live Q&A
  • 2:20 PM – 2:55 PM ET
    Session 6: Current and Emerging Therapies in Hepatocellular Carcinoma
  • 2:55 PM – 3:05 PM ET
    Live Q&A
  • 3:05 PM – 3:20 PM ET
    Exhibit Hall
  • 3:20 PM – 3:55 PM ET
    6 - Session 7: Integration of Supportive Care
  • 3:55 PM – 4:05 PM ET
    6 - Session 7: Integration of Supportive Care
  • Friday, September 29, 2023
  • 8:00 AM – 8:15 AM ET
    Welcome
  • 8:15 AM – 8:30 AM ET
    8 - Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided All RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Triplet Chemo + Bevacizumab
  • 8:30 AM – 8:45 AM ET
    9 - Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab
  • 8:45 AM – 9:00 AM ET
    9 - Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC)
  • 9:00 AM – 9:35 AM ET
    1 - Session 9: Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted Therapies
  • 9:35 AM – 9:45 AM ET
    1 - Session 9: Emerging Treatment Strategies for HER2+ mCRC: Molecular Profiling and Targeted Therapies
  • 9:45 AM – 9:50 AM ET
    Break
  • 9:50 AM – 10:50 AM ET
    Non-CME Innvoation Theater (Sponsored By AstraZeneca)
  • 10:50 AM – 11:00 AM ET
    Exhibit Hall
  • 11:00 AM – 11:35 AM ET
    18 - Session 10: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment Strategies
  • 11:35 AM – 11:45 AM ET
    18 - Session 10: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment Strategies
  • 11:45 AM – 12:20 PM ET
    1 - Session 11: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing and Targeted Treatment Strategies
  • 12:20 PM – 12:30 PM ET
    1 - Session 11: Integrating Biomarkers into the Management of Gastric Cancer: A Focus on Molecular Testing
    and Targeted Treatment Strategies
  • 12:30 PM – 12:35 PM ET
    Break
  • 12:35 PM – 1:35 PM ET
    Non-CME Innvoation Theater (Sponsored By Exelixis)
  • 1:35 PM – 2:10 PM ET
    Session 12: Therapeutic Sequencing in Advanced Colorectal Cancer: New Strategies from Clinical Trial Data
  • 2:10 PM – 2:20 PM ET
    Live Q&A
  • 2:20 PM – 2:35 PM ET
    15 - Session 13: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Yes
  • 2:35 PM – 2:50 PM ET
    15 - Session 13: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - No
  • 2:50 PM – 3:05 PM ET
    15 - Session 13: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No
  • 3:05 PM – 3:20 PM ET
    Exhibit Hall
  • 3:20 PM – 3:55 PM ET
    15 - Session 14: The Pillars of Cancer Wellness
  • 3:55 PM – 4:05 PM ET
    15 - Session 14: The Pillars of Cancer Wellness
  • 4:05 PM – 4:20 PM ET
    8 - Session 15: Debate: Pancreatic NETs: PRRT vs Chemotherapy - PRRT
  • 4:20 PM – 4:35 PM ET
    8 - Session 15: Debate: Pancreatic NETs: PRRT vs Chemotherapy - Chemotherapy
  • 4:35 PM – 4:50 PM ET
    8 - Session 15: Debate: Pancreatic NETs: PRRT vs Chemotherapy
  • 4:50 PM – 5:25 PM ET
    14 - Session 16: The Power of Patient Advocacy
  • 5:25 PM – 5:35 PM ET
    14 - Session 16: The Power of Patient Advocacy
  • Saturday, September 30, 2023
  • 8:00 AM – 8:15 AM ET
    Welcome
  • 8:15 AM – 8:50 AM ET
    Session 17: Updates from Recent Meetings
  • 8:50 AM – 9:00 AM ET
    Session 17: Updates from Recent Meetings
  • 9:00 AM – 9:35 AM ET
    Session 18: Novel Newer and Emerging Treatment Options for the Management of Non-MSI-H Metastatic Colorectal Cancer
  • 9:35 AM – 9:45 AM ET
    Session 17: Updates from Recent Meetings
  • 9:45 AM – 9:50 AM ET
    Break
  • 9:50 AM – 10:50 AM ET
    Non-CME Innovation Theater (Sponsored By Taiho Oncology)
  • 10:50 AM – 11:20 AM ET
    Exhibit Hall
  • 11:20 AM – 11:35 AM ET
    21 - Session 19: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX
  • 11:35 AM – 11:50 AM ET
    21 - Session 19: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX
  • 11:50 AM – 12:05 PM ET
    21 - Session 19: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer
  • 12:05 PM – 12:35 PM ET
    Lunch
  • 12:35 PM – 1:10 PM ET
    19 - Session 20: Significance of Cancer Genetics
  • 1:10 PM – 1:20 PM ET
    19 - Live Q&A
  • 1:20 PM – 1:55 PM ET
    21 - Session 21: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and Gastric
  • 1:55 PM – 2:05 PM ET
    21 - Live Q&A